title: GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer.
abstract: Androgen deprivation therapy (ADT) for advanced prostate cancer inexorably leads to resistance, and clinically useful biomarkers are lacking. The value of genetically engineered mice for coclinical studies is clearly demonstrated in a recent publication that reveals XAF1, XIAP, and SRD5A1 as novel predictive biomarkers and therapeutic targets for ADT resistance.
authors.affiliation: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
authors.forename: Theodoros
authors.initials: T
authors.lastname: Karantanos
authors.forename: Timothy C
authors.initials: TC
authors.lastname: Thompson
mesh_terms: D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000032:analysis; D048868:Adaptor Proteins, Signal Transducing; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000818:Animals; D051017:Apoptosis Regulatory Proteins; D004195:Disease Models, Animal; D019008:Drug Resistance, Neoplasm; D005818:Genetic Engineering; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000032:analysis; D008297:Male; D008565:Membrane Proteins / Q000032:analysis; D051379:Mice; D009363:Neoplasm Proteins / Q000032:analysis; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000726:Androgen Antagonists; D051017:Apoptosis Regulatory Proteins; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D009363:Neoplasm Proteins; C417551:XAF1 protein, human; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase; C548467:SRD5A1 protein, human